FDA staff raises concerns on Geron's blood disorder drug

The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's (GERN.O) blood disorder drug provided a clear benefit to patients in a late-stage trial and raised multiple safety concerns with the treatment.